Metabolic effects of CX3CR1 deficiency in diet-induced obese mice

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Shah, Rachana ^a   O'Neill, Sean M ^b   Hinkle, Christine ^b   Caughey, Jennifer ^b   Stephan, Stephen ^b   Lynch, Emma ^b   Bermingham, Kate ^b   Lynch, Gina ^b   Ahima, Rexford S ^b   Reilly, Muredach P ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; CHEMOKINE RECEPTOR CX3CR1; GLYCOGEN SYNTHASE KINASE 3BETA; LIPID; PROTEIN KINASE B; CHEMOKINE RECEPTOR; CX3CR1 PROTEIN, MOUSE; FRACTALKINE; GLYCOGEN SYNTHASE KINASE 3; GSK3B PROTEIN, MOUSE; INSULIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL POPULATION; CHEMOKINE RECEPTOR CX3CR1 DEFICIENCY; CONTROLLED STUDY; DIET INDUCED OBESITY; ENERGY EXPENDITURE; ENZYME PHOSPHORYLATION; FAT CONTENT; FEEDING BEHAVIOR; GLUCONEOGENESIS; GLUCOSE INFUSION; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MACROPHAGE; MALE; MONOCYTE; NONHUMAN; PROTEIN DEFICIENCY; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ADIPOSE TISSUE; ANIMAL; BLOOD; C57BL MOUSE; CYTOLOGY; DEFICIENCY; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LIVER; METABOLISM; MOUSE;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; CHEMOKINE CCL2; CHEMOKINE CX3CL1; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; ENERGY METABOLISM; GLUCOSE INTOLERANCE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; LIVER; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CHEMOKINE;

EID: 84947435413     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0138317     Document Type: Article

References (28)

1. Faure S, Meyer L, Costagliola D, Vaneensberghe C, Genin E, Autran B, et al. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science. 2000; 287(5461):2274-7. PMID: 10731151.
2. Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O, Imai T. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol. 2004; 24(1):34-40. PMID: 12969992.
3. Niess JH, Brand S, Gu X, Landsman L, Jung S, McCormick BA, et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science. 2005; 307(5707):254-8. PMID: 15653504.
4. White GE, Greaves DR. Fractalkine: one chemokine, many functions. Blood. 2009; 113(4):767-8. PMID: 19164504. doi: 10.1182/blood-2008-11-189860
5. Nishimura M, Kuboi Y, Muramoto K, Kawano T, Imai T. Chemokines as novel therapeutic targets for inflammatory bowel disease. Ann N Y Acad Sci. 2009; 1173:350-6. PMID: 19758172. doi: 10.1111/j. 1749-6632.2009.04738.x
6. Apostolakis S, Spandidos D. Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway. Acta pharmacologica Sinica. 2013; 34(10):1251-6. doi: 10.1038/aps.2013.92 PMID: 23974513.
7. Shah R, Hinkle CC, Ferguson JF, Mehta NN, Li M, Qu L, et al. Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes. 2011; 60(5):1512-8. Epub 2011/04/29. doi: 60/5/1512 [pii] doi: 10.2337/db10-0956 PMID: 21525510.
8. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997; 91(4):521-30. PMID: 9390561.
9. Combadiere C, Salzwedel K, Smith ED, Tiffany HL, Berger EA, Murphy PM. Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J Biol Chem. 1998; 273(37):23799-804. PMID: 9726990.
10. Foussat A, Coulomb-L'Hermine A, Gosling J, Krzysiek R, Durand-Gasselin I, Schall T, et al. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human. Eur J Immunol. 2000; 30(1):87-97. PMID: 10602030.
11. White GE, Greaves DR. Fractalkine: a survivor's guide: chemokines as antiapoptotic mediators. Arterioscler Thromb Vasc Biol. 2012; 32(3):589-94. doi: 10.1161/ATVBAHA.111.237412 PMID: 22247260.
12. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol. 2000; 20(11):4106-14. PMID: 10805752.
13. Cook DN, Chen SC, Sullivan LM, Manfra DJ, Wiekowski MT, Prosser DM, et al. Generation and analysis of mice lacking the chemokine fractalkine. Mol Cell Biol. 2001; 21(9):3159-65. PMID: 11287620.
14. Sirois-Gagnon D, Chamberland A, Perron S, Brisson D, Gaudet D, Laprise C. Association of Common Polymorphisms in the Fractalkine Receptor (CX3CR1) With Obesity. Obesity (Silver Spring). 2010. Epub 2010/06/05. doi: oby2010125 [pii] doi: 10.1038/oby.2010.125 PMID: 20523302.
15. Sirois-Gagnon D, Chamberland A, Perron S, Brisson D, Gaudet D, Laprise C. Association of common polymorphisms in the fractalkine receptor (CX3CR1) with obesity. Obesity (Silver Spring). 2011; 19 (1):222-7. doi: 10.1038/oby.2010.125 PMID: 20523302.
16. Lee YS, Morinaga H, Kim JJ, Lagakos W, Taylor S, Keshwani M, et al. The fractalkine/CX3CR1 system regulates beta cell function and insulin secretion. Cell. 2013; 153(2):413-25. doi: 10.1016/j.cell.2013. 03.001 PubMed Central PMCID: PMC3717389. PMID: 23582329
17. Haskell CA, Hancock WW, Salant DJ, Gao W, Csizmadia V, Peters W, et al. Targeted deletion of CX(3) CR1 reveals a role for fractalkine in cardiac allograft rejection. The Journal of clinical investigation. 2001; 108(5):679-88. Epub 2001/09/07. doi: 10.1172/JCI12976 PMID: 11544273; PubMed Central PMCID: PMC209384.
18. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS biology. 2010; 8(6):e1000412. doi: 10. 1371/journal.pbio.1000412 PMID: 20613859; PubMed Central PMCID: PMC2893951.
19. Ahima RS, Patel HR, Takahashi N, Qi Y, Hileman SM, Zasloff MA. Appetite suppression and weight reduction by a centrally active aminosterol. Diabetes. 2002; 51(7):2099-104. PMID: 12086938.
20. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB 3rd, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science. 2001; 292 (5522):1728-31. doi: 10.1126/science.292.5522.1728 PMID: 11387480.
21. McGillicuddy FC, de la Llera Moya M, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation. 2009; 119(8):1135-45. doi: 10.1161/ CIRCULATIONAHA.108.810721 PMID: 19221221.
22. Cho KW, Morris DL, Lumeng CN. Flow cytometry analyses of adipose tissue macrophages. Methods in enzymology. 2014; 537:297-314. doi: 10.1016/B978-0-12-411619-1.00016-1 PMID: 24480353.
23. Morris DL, Oatmen KE, Wang T, DelProposto JL, Lumeng CN. CX3CR1 deficiency does not influence trafficking of adipose tissue macrophages in mice with diet-induced obesity. Obesity (Silver Spring). 2012; 20(6):1189-99. doi: 10.1038/oby.2012.7 PMID: 22252034.
24. Xueyao Y, Saifei Z, Dan Y, Qianqian P, Xuehong D, Jiaqiang Z, et al. Circulating fractalkine levels predict the development of the metabolic syndrome. International journal of endocrinology. 2014; 2014:715148. doi: 10.1155/2014/715148 PMID: 24883062; PubMed Central PMCID: PMC4021752.
25. Ebert T, Hindricks J, Kralisch S, Lossner U, Jessnitzer B, Richter J, et al. Serum levels of fractalkine are associated with markers of insulin resistance in gestational diabetes. Diabetic medicine: a journal of the British Diabetic Association. 2014; 31(8):1014-7. doi: 10.1111/dme.12451 PMID: 24673545.
26. Polyak A, Ferenczi S, Denes A, Winkler Z, Kriszt R, Pinter-Kubler B, et al. The fractalkine/Cx3CR1 system is implicated in the development of metabolic visceral adipose tissue inflammation in obesity. Brain, behavior, and immunity. 2014; 38:25-35. doi: 10.1016/j.bbi.2014.01.010 PMID: 24456845.
27. Morari J, Anhe GF, Nascimento LF, de Moura RF, Razolli D, Solon C, et al. Fractalkine (CX3CL1) is involved in the early activation of hypothalamic inflammation in experimental obesity. Diabetes. 2014; 63(11):3770-84. doi: 10.2337/db13-1495 PMID: 24947351.
28. Routh VH, Hao L, Santiago AM, Sheng Z, Zhou C. Hypothalamic glucose sensing: making ends meet. Frontiers in systems neuroscience. 2014; 8:236. doi: 10.3389/fnsys.2014.00236 PMID: 25540613; PubMed Central PMCID: PMC4261699.